Amicar Disease Interactions

Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid. Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring of muscle enzymes (particularly CPK) are recommended.

Aminocaproic acid is primarily eliminated by the kidney. Approximately 65% of aminocaproic acid is excreted unchanged in the urine. Serum concentrations of aminocaproic acid can be increased in patients with renal impairment. Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding. Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy. Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

The use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.